

Mehmet Artac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8299008/publications.pdf>

Version: 2024-02-01

98
papers

1,104
citations

471061

17
h-index

476904

29
g-index

100
all docs

100
docs citations

100
times ranked

1551
citing authors

#	ARTICLE	IF	CITATIONS
1	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. <i>Pharmacogenomics</i> , 2010, 11, 1149-1167.	0.6	129
2	Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. <i>Cytokine</i> , 2004, 27, 58-65.	1.4	86
3	?Do not tell?: what factors affect relatives? attitudes to honest disclosure of diagnosis to cancer patients?. <i>Supportive Care in Cancer</i> , 2004, 12, 497-502.	1.0	67
4	Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)?. <i>Cancer</i> , 2005, 104, 2650-2657.	2.0	52
5	Factors Related to Truth-Telling Practice of Physicians Treating Patients with Cancer in Turkey. <i>Journal of Palliative Medicine</i> , 2006, 9, 1114-1119.	0.6	51
6	Leptin and breast cancer: an overview. <i>Medical Oncology</i> , 2012, 29, 1510-1514.	1.2	45
7	Durable Remission of Leptomeningeal Metastasis of Breast Cancer with Letrozole: a Case Report and Implications of Biomarkers on Treatment Selection. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 229-231.	0.6	43
8	A simple and accurate prediction model to estimate the intrahospital mortality risk of hospitalised cancer patients. <i>International Journal of Clinical Practice</i> , 2004, 58, 1014-1019.	0.8	35
9	Asymptomatic Acute Pancreatitis Due to Tamoxifen-Induced Severe Hypertriglyceridemia in a Patient with Diabetes Mellitus and Breast Cancer. <i>Journal of Chemotherapy</i> , 2002, 14, 309-311.	0.7	31
10	The relationship between nutritional status and handgrip strength in adult cancer patients: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2018, 26, 2441-2451.	1.0	25
11	Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. <i>Medical Oncology</i> , 2009, 26, 386-392.	1.2	24
12	The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 803-809.	1.2	24
13	Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Tj ETQq1 1 0.784314 rgBT /Overlock 0,4 24		
14	Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 201, 128-132.	1.0	23
15	Quality of Life in Patients With Advanced Non-Small Cell Lung Cancer. <i>Cancer Nursing</i> , 2006, 29, 104-110.	0.7	22
16	Hand carriage of <i>Candida</i> species and risk factors in hospital personnel. <i>Mycoses</i> , 2007, 50, 189-192.	1.8	21
17	Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 176-180.	0.6	20
18	Radiotherapy-induced Hypopituitarism in Nasopharyngeal Carcinoma: the Tip of an Iceberg. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2015, 123, 411-418.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 214-220.	0.6	15
20	MORPHOLOGICAL ASYMMETRY IN THYROID LOBES, AND SEX AND HANDEDNESS DIFFERENCES IN HEALTHY YOUNG SUBJECTS. <i>International Journal of Neuroscience</i> , 2006, 116, 1173-1179.	0.8	14
21	Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1275-1279.	0.4	14
22	A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. <i>Supportive Care in Cancer</i> , 2015, 23, 1759-1767.	1.0	13
23	Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2016, 16, 78.	0.9	13
24	Do High-risk Features Support the Use of Adjuvant Chemotherapy in Stage II Colon Cancer? A Turkish Oncology Group Study. <i>Tumori</i> , 2014, 100, 143-148.	0.6	12
25	Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. <i>Medical Science Monitor</i> , 2005, 11, HY11-20.	0.5	12
26	The acute effect of tropisetron on ECG parameters in cancer patients. <i>Supportive Care in Cancer</i> , 2008, 16, 1011-1015.	1.0	11
27	Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. <i>Tumori</i> , 2014, 100, 143-8.	0.6	11
28	Severe pulmonary haemorrhage accompanying hepatorenal failure in fulminant leptospirosis. <i>International Journal of Clinical Practice</i> , 2007, 61, 164-167.	0.8	10
29	Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). <i>Breast Cancer</i> , 2013, 20, 174-180.	1.3	9
30	The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 491-497.	0.6	9
31	Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: An in vitro study. <i>Cell Biology International</i> , 2006, 30, 278-282.	1.4	8
32	Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 4279-4285.	0.8	8
33	Expression of claudin 1, 4 and 7 in thyroid neoplasms. <i>Oncology Letters</i> , 2017, 13, 3722-3726.	0.8	8
34	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 131-143.	1.1	8
35	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. <i>European Urology Focus</i> , 2021, 7, 1061-1066.	1.6	8
36	Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1506-1513.	1.0	8

#	ARTICLE	IF	CITATIONS
37	A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 301-307.	0.6	8
38	Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 141-145.	0.5	7
39	A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastro-esophageal junction cancer (TOXAG study).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS182-TPS182.	0.8	7
40	Genotoxicity of Thallium-201 in Patients with Angina Pectoris Undergoing Myocardial Perfusion Study. <i>Tohoku Journal of Experimental Medicine</i> , 2005, 206, 299-304.	0.5	6
41	An Atypical Case of POEMS Syndrome with IgG Kappa M Protein and End Stage Renal Failure. <i>International Urology and Nephrology</i> , 2005, 37, 581-585.	0.6	6
42	The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors. <i>Breast</i> , 2008, 17, 418-422.	0.9	6
43	Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e347-e353.	0.9	6
44	Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. <i>Surgical Oncology</i> , 2018, 27, 485-489.	0.8	6
45	Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1091-1097.	1.1	6
46	Unusual Localization of Hydatid Cyst. <i>Clinical Nuclear Medicine</i> , 2002, 27, 449-450.	0.7	6
47	An update on the multimodality of localized rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 23-32.	2.0	5
48	The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1657-1666.	0.5	5
49	Dietary Antioxidant Capacity and Serum Inflammatory Biomarkers Levels in Cancer Survivors. <i>Nutrition and Cancer</i> , 2021, , 1-9.	0.9	5
50	Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 287.	0.3	5
51	Hemodialysis shortens long in vitro closure times as measured by the PFA-100. <i>Medical Science Monitor</i> , 2007, 13, CR141-5.	0.5	5
52	Biatrial Cardiac Metastases in a Patient with Uterine Cervix Malignant Melanoma. <i>Case Reports in Cardiology</i> , 2015, 2015, 1-5.	0.1	4
53	The preliminary effects of henna on chemotherapy-induced peripheral neuropathy in women receiving oxaliplatin-based treatment: A parallel-group, randomized, controlled pilot trial. <i>European Journal of Oncology Nursing</i> , 2020, 48, 101827.	0.9	4
54	Pemetrexed-induced Sweet Syndrome: First case report in the medical literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522096317.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?. Indian Journal of Cancer, 2015, 52, 517.	0.2	4
56	Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis. Journal of Cancer Research and Therapeutics, 2020, 16, 828.	0.3	4
57	Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer. Journal of Oncology Pharmacy Practice, 2022, 28, 740-745.	0.5	4
58	Bone Scintigraphy in Cleidocranial Dysplasia. Clinical Nuclear Medicine, 2004, 29, 65-67.	0.7	3
59	Brucellosis in febrile neutropenia. Leukemia and Lymphoma, 2007, 48, 827-828.	0.6	3
60	Vaginal metastasis in solid tumours: our four cases and review of the literature. Journal of the Egyptian National Cancer Institute, 2021, 33, 3.	0.6	3
61	A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastroesophageal junction cancer (TOXAG study).. Journal of Clinical Oncology, 2018, 36, 26-26.	0.8	3
62	Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4127-4131.	0.5	3
63	Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2013, 23, 1-6.	0.1	2
64	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. Journal of Gastrointestinal Cancer, 2016, 47, 264-272.	0.6	2
65	Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study. Journal of Health Psychology, 2018, 23, 561-566.	1.3	2
66	Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2021, 27, 405-413.	0.5	2
67	Response to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells. Clinical and Experimental Medicine, 2021, 21, 447-456.	1.9	2
68	The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. Journal of Gastrointestinal Cancer, 2022, 53, 356-362.	0.6	2
69	Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor. Journal of Oncology Pharmacy Practice, 2021, 27, 2049-2052.	0.5	2
70	Circular analyses of dates on patients with gastric carcinoma. Journal of Applied Statistics, 2021, 48, 2931-2943.	0.6	2
71	The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.. Journal of Clinical Oncology, 2018, 36, e15553-e15553.	0.8	2
72	Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study. Journal of Oncological Science, 2020, 6, 87-95.	0.1	2

#	ARTICLE	IF	CITATIONS
73	The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 816.	0.3	2
74	Prognostic Value of Systemic Immune-Inflammation Index in Patients with Testicular Cancer: A Retrospective Case-Control Study. <i>Acronkoloji Bülteni</i> , 2021, 20, 252-257.	0.1	2
75	Incidental Detection of Atelectasis on Tc-99m MDP Bone Scans. <i>Clinical Nuclear Medicine</i> , 2004, 29, 70-71.	0.7	1
76	A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib. <i>Journal of Oncological Science</i> , 2018, 4, 111-113.	0.1	1
77	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 932-939.	0.6	1
78	Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097847.	0.5	1
79	Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 409-409.	0.8	1
80	Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11586-e11586.	0.8	1
81	Chronic Myeloid Leukemia After Chemoradiotherapy in a Patient with Non-Small Cell Lung Cancer. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2017, 27, 256-257.	0.1	1
82	Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 451-451.	0.8	1
83	Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110737.	0.5	1
84	A case of severe vasculitis after FLOT chemotherapy in a patient with metastatic gastric cancer who received multiple line chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210740.	0.5	1
85	Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2022, , 1.	0.6	1
86	Compensatory Hypertrophy of the Left Liver Lobe. <i>Clinical Nuclear Medicine</i> , 2003, 28, 445-446.	0.7	0
87	The Debate About Maintenance Is Not Over in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5840-5840.	0.8	0
88	Body Mass Index and Colorectal Cancer. , 2019, , .		0
89	Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1623-1630.	0.5	0
90	First renal metastasis report from tongue cancer. <i>Brazilian Journal of Otorhinolaryngology</i> , 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 805-812.	1.1	0
92	Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients?. <i>Journal of Clinical Oncology</i> , 2012, 30, e11008-e11008.	0.8	0
93	Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis. <i>Electronic Journal of General Medicine</i> , 2012, 9, 265-269.	0.3	0
94	Relation of metastatic stage at the diagnosis of non-small cell lung cancer (NSCLC) to XRCC1 and TP53 single nucleotide polymorphisms (SNPs).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19109-e19109.	0.8	0
95	Abstract 718: The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report. , 2015, , .		0
96	Survivin Expression May Affect The Neoadjuvant Chemotherapy Response in Breast Cancer Patients. <i>Eastern Journal of Medicine</i> , 2017, 22, 147-154.	0.1	0
97	Perineural invasion is a better prognostic factor than extranodal extension in head and neck cancer. <i>The Egyptian Journal of Otolaryngology</i> , 2022, 38, .	0.1	0
98	The goal of primary therapy in non-metastatic nasopharyngeal cancer should be radiological complete response. <i>The Egyptian Journal of Otolaryngology</i> , 2022, 38, .	0.1	0